DexCom, Inc. DXCM
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.34B | 1.31B | 1.19B | 1.26B | 1.21B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.34B | 1.31B | 1.19B | 1.26B | 1.21B |
| Cost of Revenue | 480.10M | 478.40M | 441.60M | 466.90M | 477.90M |
| Gross Profit | 864.40M | 830.00M | 750.30M | 792.70M | 731.40M |
| SG&A Expenses | 375.60M | 358.70M | 349.70M | 321.50M | 331.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.02B | 990.10M | 936.60M | 936.60M | 966.80M |
| Operating Income | 327.20M | 318.30M | 255.30M | 323.00M | 242.50M |
| Income Before Tax | 334.70M | 317.50M | 269.50M | 340.70M | 352.30M |
| Income Tax Expenses | 59.60M | 68.40M | 70.00M | 73.40M | 68.50M |
| Earnings from Continuing Operations | 275.10M | 249.10M | 199.50M | 267.30M | 283.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 275.10M | 249.10M | 199.50M | 267.30M | 283.80M |
| EBIT | 327.20M | 318.30M | 255.30M | 323.00M | 242.50M |
| EBITDA | 401.70M | 386.50M | 322.40M | 388.20M | 306.10M |
| EPS Basic | 0.73 | 0.65 | 0.52 | 0.69 | 0.73 |
| Normalized Basic EPS | 0.56 | 0.54 | 0.44 | 0.55 | 0.43 |
| EPS Diluted | 0.72 | 0.64 | 0.51 | 0.68 | 0.70 |
| Normalized Diluted EPS | 0.55 | 0.52 | 0.43 | 0.53 | 0.41 |
| Average Basic Shares Outstanding | 374.70M | 382.20M | 385.10M | 386.70M | 391.10M |
| Average Diluted Shares Outstanding | 383.50M | 390.10M | 393.60M | 398.90M | 407.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |